Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Aerobiosis
/ drug effects
Animals
Cell Proliferation
/ drug effects
Cell Respiration
/ drug effects
Crotonates
/ pharmacology
Dihydroorotate Dehydrogenase
Electron Transport Complex III
/ metabolism
Energy Metabolism
/ drug effects
Gene Expression Regulation
/ drug effects
Glycolysis
/ drug effects
Humans
Hydroxybutyrates
Lymphocyte Activation
/ drug effects
Lymphocyte Subsets
/ drug effects
Mitochondria
/ drug effects
Multiple Sclerosis
/ drug therapy
Multiple Sclerosis, Relapsing-Remitting
/ immunology
Nitriles
Oxidative Phosphorylation
/ drug effects
Oxidoreductases Acting on CH-CH Group Donors
/ antagonists & inhibitors
Receptors, Antigen, T-Cell
/ metabolism
T-Lymphocytes
/ drug effects
Toluidines
/ pharmacology
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
01 05 2019
01 05 2019
Historique:
received:
18
08
2017
revised:
20
08
2018
accepted:
02
04
2019
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
27
6
2020
Statut:
ppublish
Résumé
Interference with immune cell proliferation represents a successful treatment strategy in T cell-mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (MS). One prominent example is pharmacological inhibition of dihydroorotate dehydrogenase (DHODH), which mediates de novo pyrimidine synthesis in actively proliferating T and B lymphocytes. Within the TERIDYNAMIC clinical study, we observed that the DHODH inhibitor teriflunomide caused selective changes in T cell subset composition and T cell receptor repertoire diversity in patients with relapsing-remitting MS (RRMS). In a preclinical antigen-specific setup, DHODH inhibition preferentially suppressed the proliferation of high-affinity T cells. Mechanistically, DHODH inhibition interferes with oxidative phosphorylation (OXPHOS) and aerobic glycolysis in activated T cells via functional inhibition of complex III of the respiratory chain. The affinity-dependent effects of DHODH inhibition were closely linked to differences in T cell metabolism. High-affinity T cells preferentially use OXPHOS during early activation, which explains their increased susceptibility toward DHODH inhibition. In a mouse model of MS, DHODH inhibitory treatment resulted in preferential inhibition of high-affinity autoreactive T cell clones. Compared to T cells from healthy controls, T cells from patients with RRMS exhibited increased OXPHOS and glycolysis, which were reduced with teriflunomide treatment. Together, these data point to a mechanism of action where DHODH inhibition corrects metabolic disturbances in T cells, which primarily affects profoundly metabolically active high-affinity T cell clones. Hence, DHODH inhibition may promote recovery of an altered T cell receptor repertoire in autoimmunity.
Identifiants
pubmed: 31043571
pii: 11/490/eaao5563
doi: 10.1126/scitranslmed.aao5563
pii:
doi:
Substances chimiques
Crotonates
0
Dihydroorotate Dehydrogenase
0
Hydroxybutyrates
0
Nitriles
0
Receptors, Antigen, T-Cell
0
Toluidines
0
teriflunomide
1C058IKG3B
Oxidoreductases Acting on CH-CH Group Donors
EC 1.3.-
Electron Transport Complex III
EC 7.1.1.8
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.